Annual FCF
-$22.91 M
+$3.65 M+13.75%
December 31, 2023
Summary
- As of February 7, 2025, BLRX annual free cash flow is -$22.91 million, with the most recent change of +$3.65 million (+13.75%) on December 31, 2023.
- During the last 3 years, BLRX annual FCF has risen by +$301.00 thousand (+1.30%).
- BLRX annual FCF is now -312.04% below its all-time high of $10.80 million, reached on December 31, 2010.
Performance
BLRX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$9.82 M
+$1.53 M+13.48%
September 1, 2024
Summary
- As of February 7, 2025, BLRX quarterly free cash flow is -$9.82 million, with the most recent change of +$1.53 million (+13.48%) on September 1, 2024.
- Over the past year, BLRX quarterly FCF has increased by +$103.00 thousand (+1.04%).
- BLRX quarterly FCF is now -154.22% below its all-time high of $18.12 million, reached on September 30, 2010.
Performance
BLRX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$30.35 M
+$103.00 K+0.34%
September 1, 2024
Summary
- As of February 7, 2025, BLRX TTM free cash flow is -$30.35 million, with the most recent change of +$103.00 thousand (+0.34%) on September 1, 2024.
- Over the past year, BLRX TTM FCF has increased by +$3.44 million (+10.18%).
- BLRX TTM FCF is now -334.33% below its all-time high of $12.95 million, reached on September 30, 2010.
Performance
BLRX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
BLRX Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +13.8% | +1.0% | +10.2% |
| 3 y3 years | +1.3% | -96.1% | -28.9% |
| 5 y5 years | +33.4% | -96.1% | -28.9% |
BLRX Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +13.8% | -297.6% | +30.5% | -34.8% | +10.2% |
| 5 y | 5-year | -0.7% | +13.8% | -297.6% | +30.5% | -34.8% | +10.2% |
| alltime | all time | -312.0% | +33.4% | -154.2% | +35.5% | -334.3% | +11.8% |
BioLineRx Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$9.82 M(-13.5%) | -$30.35 M(-0.3%) |
| Jun 2024 | - | -$11.36 M(-19.7%) | -$30.45 M(+5.4%) |
| Mar 2024 | - | -$14.14 M(-384.4%) | -$28.90 M(+26.2%) |
| Dec 2023 | -$22.91 M(-13.7%) | $4.97 M(-150.1%) | -$22.91 M(-32.2%) |
| Sep 2023 | - | -$9.93 M(+1.3%) | -$33.79 M(+3.7%) |
| Jun 2023 | - | -$9.80 M(+20.4%) | -$32.57 M(+11.9%) |
| Mar 2023 | - | -$8.14 M(+37.8%) | -$29.10 M(+9.6%) |
| Dec 2022 | -$26.56 M(+12.2%) | -$5.91 M(-32.1%) | -$26.56 M(+1.3%) |
| Sep 2022 | - | -$8.71 M(+37.5%) | -$26.21 M(+16.4%) |
| Jun 2022 | - | -$6.33 M(+13.0%) | -$22.51 M(-2.2%) |
| Mar 2022 | - | -$5.60 M(+0.7%) | -$23.03 M(-2.7%) |
| Dec 2021 | -$23.67 M(+2.0%) | -$5.57 M(+11.1%) | -$23.67 M(+0.6%) |
| Sep 2021 | - | -$5.01 M(-26.8%) | -$23.54 M(-1.9%) |
| Jun 2021 | - | -$6.85 M(+9.6%) | -$24.00 M(+5.6%) |
| Mar 2021 | - | -$6.25 M(+15.0%) | -$22.72 M(-2.1%) |
| Dec 2020 | -$23.21 M(+2.1%) | -$5.43 M(-0.7%) | -$23.21 M(-0.1%) |
| Sep 2020 | - | -$5.47 M(-1.7%) | -$23.22 M(-2.9%) |
| Jun 2020 | - | -$5.57 M(-17.4%) | -$23.92 M(-3.6%) |
| Mar 2020 | - | -$6.74 M(+23.7%) | -$24.82 M(+9.2%) |
| Dec 2019 | -$22.74 M(-33.9%) | -$5.45 M(-11.7%) | -$22.74 M(-30.1%) |
| Sep 2019 | - | -$6.17 M(-4.6%) | -$32.53 M(+0.5%) |
| Jun 2019 | - | -$6.47 M(+39.0%) | -$32.38 M(+0.6%) |
| Mar 2019 | - | -$4.65 M(-69.5%) | -$32.17 M(-6.5%) |
| Dec 2018 | -$34.41 M(+38.8%) | -$15.24 M(+153.4%) | -$34.41 M(+32.9%) |
| Sep 2018 | - | -$6.01 M(-4.0%) | -$25.90 M(-0.8%) |
| Jun 2018 | - | -$6.26 M(-9.1%) | -$26.12 M(+8.3%) |
| Mar 2018 | - | -$6.89 M(+2.3%) | -$24.12 M(-2.7%) |
| Dec 2017 | -$24.79 M | -$6.73 M(+8.0%) | -$24.79 M(+12.6%) |
| Sep 2017 | - | -$6.24 M(+46.4%) | -$22.00 M(+17.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2017 | - | -$4.26 M(-43.6%) | -$18.75 M(+5.4%) |
| Mar 2017 | - | -$7.56 M(+91.2%) | -$17.79 M(+22.1%) |
| Dec 2016 | -$14.57 M(-13.7%) | -$3.95 M(+32.5%) | -$14.57 M(+3.8%) |
| Sep 2016 | - | -$2.98 M(-9.7%) | -$14.04 M(-11.1%) |
| Jun 2016 | - | -$3.30 M(-23.8%) | -$15.78 M(-10.3%) |
| Mar 2016 | - | -$4.33 M(+26.7%) | -$17.60 M(+4.2%) |
| Dec 2015 | -$16.89 M(+5.9%) | -$3.42 M(-27.7%) | -$16.89 M(-7.6%) |
| Sep 2015 | - | -$4.73 M(-7.6%) | -$18.27 M(+8.4%) |
| Jun 2015 | - | -$5.12 M(+41.4%) | -$16.86 M(+4.5%) |
| Mar 2015 | - | -$3.62 M(-24.7%) | -$16.12 M(+1.1%) |
| Dec 2014 | -$15.94 M(-18.8%) | -$4.81 M(+45.1%) | -$15.94 M(+6.1%) |
| Sep 2014 | - | -$3.31 M(-24.5%) | -$15.03 M(-6.2%) |
| Jun 2014 | - | -$4.39 M(+27.6%) | -$16.02 M(-10.0%) |
| Mar 2014 | - | -$3.44 M(-11.6%) | -$17.81 M(-9.3%) |
| Dec 2013 | -$19.64 M(-3.2%) | -$3.89 M(-9.7%) | -$19.64 M(-12.9%) |
| Sep 2013 | - | -$4.31 M(-30.2%) | -$22.55 M(+1.1%) |
| Jun 2013 | - | -$6.17 M(+17.1%) | -$22.31 M(+1.5%) |
| Mar 2013 | - | -$5.27 M(-22.5%) | -$21.98 M(+8.3%) |
| Dec 2012 | -$20.29 M(+76.3%) | -$6.80 M(+67.3%) | -$20.29 M(+15.4%) |
| Sep 2012 | - | -$4.07 M(-30.4%) | -$17.59 M(+21.1%) |
| Jun 2012 | - | -$5.84 M(+62.8%) | -$14.53 M(+15.3%) |
| Mar 2012 | - | -$3.59 M(-12.5%) | -$12.60 M(+9.5%) |
| Dec 2011 | -$11.51 M(-206.5%) | -$4.10 M(+307.2%) | -$11.51 M(+20.4%) |
| Sep 2011 | - | -$1.01 M(-74.2%) | -$9.56 M(-199.9%) |
| Jun 2011 | - | -$3.90 M(+56.4%) | $9.57 M(-14.6%) |
| Mar 2011 | - | -$2.50 M(+16.2%) | $11.21 M(+3.8%) |
| Dec 2010 | $10.80 M | -$2.15 M(-111.9%) | $10.80 M(-16.6%) |
| Sep 2010 | - | $18.12 M(-900.9%) | $12.95 M(-350.6%) |
| Jun 2010 | - | -$2.26 M(-22.1%) | -$5.17 M(+77.9%) |
| Mar 2010 | - | -$2.91 M | -$2.91 M |
FAQ
- What is BioLineRx annual free cash flow?
- What is the all time high annual FCF for BioLineRx?
- What is BioLineRx annual FCF year-on-year change?
- What is BioLineRx quarterly free cash flow?
- What is the all time high quarterly FCF for BioLineRx?
- What is BioLineRx quarterly FCF year-on-year change?
- What is BioLineRx TTM free cash flow?
- What is the all time high TTM FCF for BioLineRx?
- What is BioLineRx TTM FCF year-on-year change?
What is BioLineRx annual free cash flow?
The current annual FCF of BLRX is -$22.91 M
What is the all time high annual FCF for BioLineRx?
BioLineRx all-time high annual free cash flow is $10.80 M
What is BioLineRx annual FCF year-on-year change?
Over the past year, BLRX annual free cash flow has changed by +$3.65 M (+13.75%)
What is BioLineRx quarterly free cash flow?
The current quarterly FCF of BLRX is -$9.82 M
What is the all time high quarterly FCF for BioLineRx?
BioLineRx all-time high quarterly free cash flow is $18.12 M
What is BioLineRx quarterly FCF year-on-year change?
Over the past year, BLRX quarterly free cash flow has changed by +$103.00 K (+1.04%)
What is BioLineRx TTM free cash flow?
The current TTM FCF of BLRX is -$30.35 M
What is the all time high TTM FCF for BioLineRx?
BioLineRx all-time high TTM free cash flow is $12.95 M
What is BioLineRx TTM FCF year-on-year change?
Over the past year, BLRX TTM free cash flow has changed by +$3.44 M (+10.18%)